X

Trial Profile

A randomised phase III study of docetaxel versus active symptom control in patients with relapsed oesophago-gastric adenocarcinoma.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Therapeutic Use
Acronyms COUGAR02

Most Recent Events

12 Mar 2014 Acruel to date is 102%.according to United Kingdom Clinical Research Network record.
04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
26 Jan 2013 Results presented at the 2013 Gastrointestinal Cancers Symposium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com